In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Impact of exercise training on the ischemic threshold- Results of the Leipzig EXerCIse Training versus mEdical management in patients with stable coronary artery disease (EXCITE) trial

Session Poster session 1

Speaker Madlen Uhlemann

Congress : ESC Congress 2016

  • Topic : basic science
  • Sub-topic : Microcirculation, Angiogenesis, Arteriogenesis
  • Session type : Poster Session
  • FP Number : P971

Authors : M Uhlemann (Leipzig,DE), S Moebius-Winkler (Weissenfels,DE), S Erbs (Leipzig,DE), A Linke (Leipzig,DE), V Adams (Leipzig,DE), J Adam (Leipzig,DE), G Schuler (Leipzig,DE)

15 views

Authors:
M. Uhlemann1 , S. Moebius-Winkler2 , S. Erbs1 , A. Linke1 , V. Adams1 , J. Adam1 , G. Schuler1 , 1University of Leipzig, Heart Center, Department of Internal Medicine and Cardiology - Leipzig - Germany , 2Asklepios Klinik, Internal Medicine/Cardiology - Weissenfels - Germany ,

Citation:
European Heart Journal ( 2016 ) 37 ( Abstract Supplement ), 187

Background: Exercise training leads to an improvement of the coronary collateral circulation. However, clinical relevance of coronary collaterals is still controversial with the association between collateral growth and ischemic threshold still unclear.

Purpose: We aimed to investigate in the impact of exercise training on the ischemic threshold. In addition, we elucidated the association between the change in coronary collateral growth and ischemic threshold.

Methods: We randomized 60 patients with significant CAD (FFR≤0.75) to high-intensity exercise (group A, 20 patients) or moderate-intensity exercise (group B, 20 patients) for 4 weeks or to a control group (group C, 20 patients). At baseline and after 4 weeks, the coronary collateral flow index (CFI) was measured invasively and the ischemic threshold was assessed in ergospirometry expressed in heart rate and watt.

Results: Four weeks of exercise training resulted in a significant increase in ischemic threshold as compared to usual care with no difference between the high- and moderate-intensities. Spearman rank correlation revealed a significant association between the change in CFI and change in ischemic threshold after 4 weeks (Spearman correlation coefficient 0.425, p=0.006). Mean heart rate at ischemic threshold assessed in ergospirometry at baseline was 113±18 bpm with no statistical differences between groups (P=0.30). At 4 weeks, we observed a significant increase in heart rate at ischemic threshold in patients who underwent exercise training compared to the control group (group A compared to group C: P=0.015; group B compared to group C: P=0.001) with no difference between high- and moderate intensities (P=1.0). In detail, after 4 weeks, mean heart rate at ischemic threshold increased from 118±19 bpm to 132±20 bpm in group A and from 107±22 bpm to 132±21 bpm in group B. We noted no change in mean heart rate at ischemic threshold after 4 weeks in group C (from 116±13 bpm to 117±13 bpm).

Conclusion: High- and moderate-intensity exercise training for 4 weeks resulted in a significant increase in ischemic threshold. In addition, we observed a significant correlation between change in CFI and change in ischemic threshold after 4 weeks (P=0.034, correlation coefficient 0.336).



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are